Researchers have developed a non-invasive imaging technique using near-infrared light that can detect kidney cell damage without biopsies. According to Gram Research analysis, this method successfully identified kidney injury across multiple disease models and tracked treatment effectiveness by measuring natural fluorescence from a compound called coproporphyrin III that accumulates in damaged cells. In 34 human kidney samples, the fluorescence signal correlated with kidney function and tissue damage scores, suggesting the technique could eventually replace painful biopsies for monitoring kidney disease.
Scientists have developed a groundbreaking way to detect kidney injury without invasive procedures. Using a special near-infrared light imaging technique, researchers can now see kidney damage in real-time by measuring natural fluorescence from injured cells. According to Gram Research analysis, this non-invasive method successfully identified kidney injury across multiple disease models and even tracked how well treatments were working. The technique works by detecting a buildup of a natural compound called coproporphyrin III that accumulates when kidney cells are stressed or damaged. This discovery could transform how doctors monitor kidney disease progression and test new treatments, potentially eliminating the need for painful kidney biopsies.
Key Statistics
A 2026 research study published in Kidney International found that near-infrared autofluorescence imaging successfully detected kidney cell injury across three different mouse disease models without requiring invasive biopsies or external contrast agents.
In 34 human kidney samples examined ex vivo, near-infrared autofluorescence signal inversely correlated with eGFR (kidney function) and positively correlated with microscopic injury scores, demonstrating the technique’s accuracy in human tissue.
When researchers administered finerenone, a kidney-protective drug, to injured mice, the autofluorescence signal decreased and kidney tissue damage improved, demonstrating the imaging technique’s ability to track therapeutic responses in real-time.
The research identified coproporphyrin III, a natural byproduct of heme metabolism, as the primary fluorophore responsible for the detectable signal, with the compound accumulating specifically in damaged kidney cells where enzyme activity is reduced.
The Quick Take
- What they studied: Whether a special type of light imaging could detect kidney cell damage without needing to remove tissue samples or use injected dyes
- Who participated: Three different mouse disease models (with different types of kidney injury), kidney tissue samples from 34 human patients, and laboratory kidney tissue cultures
- Key finding: Near-infrared autofluorescence imaging successfully detected kidney damage and tracked treatment effectiveness across all models, with results matching traditional biopsy findings
- What it means for you: This could eventually allow doctors to monitor kidney disease and test treatments without painful biopsies, though human clinical trials are still needed before it becomes available in hospitals
The Research Details
Researchers used a non-invasive imaging technique that detects natural light emitted from kidney cells when exposed to near-infrared light. They tested this approach in three different mouse models that mimic different types of kidney injury: obstruction (blocked urine flow), toxin-induced damage, and ischemia-reperfusion injury (temporary loss of blood flow). The team also examined human kidney samples from 34 patients to see if the results would translate to people.
To understand how the imaging works, scientists identified that a natural compound called coproporphyrin III accumulates in damaged kidney cells and produces the detectable fluorescence signal. They confirmed this by studying mice with a genetic mutation that causes this compound to build up, and by treating kidney tissue cultures with drugs that either increased or decreased the signal.
Finally, the researchers tested whether the imaging could track whether treatments were working by giving mice a kidney-protective drug called finerenone and measuring changes in the fluorescence signal over time.
Current methods for assessing kidney damage either require invasive biopsies (removing tissue samples) or lack the ability to monitor changes in real-time. This new approach offers a non-invasive alternative that could enable doctors to continuously monitor disease progression and immediately see whether treatments are working, without exposing patients to the risks and discomfort of repeated biopsies.
The study demonstrates strong internal validity by using multiple independent disease models that all showed consistent results. The findings were validated in human tissue samples, suggesting potential for clinical translation. The mechanistic studies clearly identified the biological basis for the fluorescence signal. However, this is proof-of-concept research in animal models and human tissue samples—human clinical trials are still needed to confirm safety and effectiveness in living patients.
What the Results Show
Near-infrared autofluorescence imaging successfully detected kidney cell injury across all three mouse disease models tested. The fluorescence signal correlated strongly with established markers of kidney damage, including oxidative stress (cellular damage from reactive oxygen species) and fibrosis (scarring). Importantly, the imaging results matched what researchers saw under microscopes in traditional tissue samples, validating the technique’s accuracy.
The research identified coproporphyrin III—a natural byproduct of the body’s heme production process—as the primary source of the fluorescence signal. When kidney cells are injured, they lose the ability to properly process this compound, causing it to accumulate and emit detectable light. This mechanism was confirmed in multiple ways: through genetic studies in mice with reduced enzyme activity, through drug experiments that manipulated the signal, and through chemical analysis that directly measured the compound’s accumulation.
When researchers administered finerenone, a kidney-protective drug, to injured mice, the fluorescence signal decreased and kidney tissue damage improved. This demonstrates that the imaging technique can track therapeutic responses in real-time, potentially allowing doctors to assess treatment effectiveness without waiting for traditional biopsy results.
In human kidney samples from 34 patients, the autofluorescence signal inversely correlated with eGFR (estimated glomerular filtration rate, a standard measure of kidney function)—meaning stronger fluorescence indicated worse kidney function. The signal also positively correlated with injury scores from microscopic examination, further validating the technique’s accuracy in human tissue. These findings suggest the imaging approach would translate well from animal models to clinical use.
This research advances beyond previous kidney injury assessment methods by offering real-time, non-invasive monitoring without requiring external dyes or contrast agents. Traditional approaches rely on invasive biopsies (which are painful and carry infection risks), blood tests (which only show kidney function after significant damage has occurred), or imaging with injected contrast agents (which can themselves harm kidney function). This technique uses the body’s own natural fluorescence, eliminating these limitations.
This is proof-of-concept research conducted primarily in animal models and human tissue samples outside the body. The study does not include living human subjects, so safety and effectiveness in patients remain unproven. The research was conducted in controlled laboratory settings; real-world clinical use would require development of specialized imaging equipment and validation in diverse patient populations. Additionally, the study focused on specific types of kidney injury; effectiveness across all kidney diseases remains unknown. Long-term follow-up data showing whether the imaging predicts clinical outcomes is not yet available.
The Bottom Line
This research provides strong proof-of-concept for a non-invasive kidney injury imaging technique, but clinical application is not yet available. For patients with kidney disease, current standard monitoring (blood tests, urine tests, and occasional biopsies when needed) remains the appropriate approach. Researchers and kidney specialists should monitor development of this technology as it moves toward human clinical trials. Confidence level: High for the scientific validity of the technique in controlled settings; Low for immediate clinical recommendations until human trials are completed.
Kidney disease patients and their doctors should be aware of this emerging technology as a potential future monitoring tool. Researchers studying kidney disease will find immediate value in using this technique for preclinical studies. Pharmaceutical companies developing kidney-protective drugs could use this imaging to accelerate drug testing. People at risk for kidney disease (those with diabetes, high blood pressure, or family history) should understand that better monitoring tools are in development.
This technology is currently in the research phase. Based on typical development timelines, human clinical trials could begin within 2-5 years, with potential clinical availability in 5-10 years if trials are successful. Immediate applications are limited to research settings.
Frequently Asked Questions
Can this new kidney imaging technique replace kidney biopsies?
This technique shows promise as a non-invasive alternative to biopsies in research settings, but human clinical trials are still needed. Currently, kidney biopsies remain the standard when tissue diagnosis is required, though this imaging could eventually reduce how often they’re needed for monitoring disease progression.
How does near-infrared autofluorescence imaging detect kidney damage?
The technique detects natural light emitted from a compound called coproporphyrin III that accumulates in injured kidney cells. When kidney cells are damaged, they lose the ability to properly process this natural byproduct of heme metabolism, causing it to build up and emit detectable fluorescence when exposed to near-infrared light.
Is this imaging technique available for patients with kidney disease right now?
No, this is currently proof-of-concept research. The technique has been validated in animal models and human tissue samples, but human clinical trials are needed before it becomes available in hospitals. Development toward clinical use could take 5-10 years if trials are successful.
What types of kidney disease can this imaging detect?
The research tested three specific types of kidney injury in mice: obstruction-related injury, toxin-induced damage, and ischemia-reperfusion injury. While results were validated in human samples, effectiveness across all kidney diseases remains unknown and would require further clinical testing.
Could this imaging help doctors test new kidney disease treatments faster?
Yes, researchers can immediately use this technique in preclinical studies to track how experimental treatments affect kidney damage in real-time without biopsies. This could accelerate drug development, though clinical translation for patient monitoring still requires human trials.
Want to Apply This Research?
- Once this imaging technology becomes clinically available, users could track kidney health by logging imaging results alongside standard kidney function tests (eGFR and creatinine levels), noting the date and any changes in fluorescence signal intensity to monitor disease progression over time.
- Users with kidney disease could use the app to set reminders for imaging appointments and correlate imaging results with lifestyle factors (diet, hydration, medication adherence, exercise) to identify which behaviors most impact their kidney health based on real-time imaging feedback.
- Establish a baseline imaging measurement, then schedule follow-up imaging at regular intervals (quarterly or semi-annually depending on disease severity). Track trends in the fluorescence signal over months and years, comparing changes to kidney function tests and treatment adjustments to build a personalized picture of disease progression and treatment response.
This research represents proof-of-concept findings in animal models and human tissue samples. The near-infrared autofluorescence imaging technique is not yet available for clinical use in patients. Current standard methods for assessing kidney disease (blood tests, urine tests, and biopsies when clinically indicated) remain the appropriate diagnostic approach. Anyone with kidney disease should continue working with their healthcare provider using established diagnostic and monitoring methods. This article is for educational purposes and should not be interpreted as medical advice. Consult with a nephrologist or kidney specialist regarding your individual kidney health assessment and monitoring needs.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.